


Application No. 09/925,224
June 21, 2002
Page 2

4. (Amended) A compound having the general structure:




wherein R₁, R₇ and R₈ are independently selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂[, with the proviso that at least one of R₁, R₇ and R₈ is other than H].

5. (Amended) The compound of claim 4 wherein R₇ and R₈ are H;
R₁ is H or F; and
R₃ is hydroxy or -OCONH₂.

6. (Amended) A method for treating a patient suffering from a neurological disorder, said method comprising the step of administering a composition comprising a compound [selected from the group consisting of] represented by the formula




wherein [R₁] R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂; and

R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H].

7. (Amended) The method of claim 6 wherein said compound has the general structure




wherein [R₁] R₉ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂.

8. (Amended) The method of claim 7 wherein [R₁] R₉ is H or halo; and R₃ is -OCONH₂.

9. (Amended) A method for preventing or limiting tissue damage resulting from an ischemic event [treating a patient suffering from tissue damage resulting from localized hypoxic conditions], said method comprising the step of administering a composition comprising a compound selected from the group consisting of




wherein [R₁] R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R₃ is hydroxy or -OCONH₂; and

R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H.]

10. (Amended) The method of claim 9 wherein said compound has the general structure




wherein [R₁] R₉ is selected from the group consisting of H, halo, haloalkyl and hydroxy; and R₃ is hydroxy or -OCONH₂.

11. (Amended) The method of claim 10 wherein [R₁] R₉ is H or halo; and R₃ is -OCONH₂.

12. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by cerebral ischemia.

13. (Amended) The method of claim 9 wherein the [localized hypoxic condition] tissue damage is caused by myocardial ischemia.

14. (Amended) A pharmaceutical composition comprising a compound selected from the group consisting of




wherein [R₁] R₇, R₈ and R₉ are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy;

R₃ is hydroxy or -OCONH₂; and

[R₄ is hydroxy or carbonyl, with the proviso that when R₉ is H, R₇ and R₈ are not both H; and]

a pharmaceutically acceptable carrier[.]


15. (Amended) The composition of claim 14 wherein said compound has the general structure



Please add new claims 18-27 as follows:

18. The composition of claim 15 wherein R₉ is H or F; and R₃ is hydroxy.

19. A compound having the general structure:



wherein R₁, R₇, R₈, R₉ and R₁₀ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, -NR₅R₆, hydroxy, and alkoxy;

R₂ is F or Cl;

R₃ is hydroxy or -OCONH₂; and

R₅ and R₆ are independently C₁-C₄ alkyl.

20. The compound of claim 19 wherein

R₁ and R₇ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₈, R₉ and R₁₀ are H.

21. The compound of claim 19 wherein

R₁ and R₈ are independently selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₇, R₉ and R₁₀ are H.

22. The compound of claim 19 wherein

R₁ is selected from the group consisting of H, halo, alkyl, haloalkyl, and hydroxy;

R₂ is F;

R₃ is hydroxy or -OCONH₂; and

R₇, R₈, R₉ and R₁₀ are H.

A


23. The compound of claim 22 wherein
 R_1 is selected from the group consisting of H, F, Cl, CF_3 and hydroxy.

24. The compound of claim 23 wherein
 R_1 is F.

25. A pharmaceutical composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

26. A pharmaceutical composition comprising the compound of claim 22 and a pharmaceutically acceptable carrier.

27. A method for reducing the incidence and severity of an epileptic seizure in an individual, said method comprising the step of administering to said individual a compound represented by the general structure:



wherein R_1 , R_7 and R_8 are independently selected from the group consisting of H, halo, alkyl, haloalkyl and hydroxy; and

R_3 is hydroxy or $-OCO NH_2$.

28. The method of claim 27 wherein R_1 is H or F, and R_7 and R_8 are H.

29. The method of claim 28 wherein R_3 is $-OCO NH_2$.